The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H- chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice

Archives of Pharmacal Research

Volumn 36, Issue 7, 2013, Pages 854-863

  Liu, Xiaotong ^a   Hong, Sung In ^f   Park, Se Jin ^a   Dela Peña, June Bryan ^c   Che, Haiyan ^b   Yoon, Seo Young ^c   Kim, Dong Hyun ^a   Kim, Jong Min ^a   Cai, Mudan ^a   Risbrough, Victoria ^e   Geyer, Mark A ^e   Shin, Chan Young ^d   Cheong, Jae Hoon ^c   Park, Haeil ^b   Lew, Jae Hwan ^a,f   Ryu, Jong Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Kangwon National University   (South Korea)

^c Sahmyook University   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Kyung Hee University College of Medicine   (South Korea)

Author keywords

Cognitive dysfunction; Oroxylin A derivative; Schizophrenia; Sensorimotor gating deficit

Indexed keywords

5,7 DIHYDROXY 6 METHOXY 2 (4 PHENOXYPHENYL) 4H CHROMENE 4 ONE; DIZOCILPINE; OROXYLIN A; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PERCEPTION DISORDER; PREPULSE INHIBITION; SENSORIMOTOR GATING DEFICIT; SENSORY GATING; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANIMALS; AVOIDANCE LEARNING; FLAVONOIDS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NAD(P)H DEHYDROGENASE (QUINONE); SENSORY GATING; STARTLE REACTION; TREATMENT OUTCOME;

EID: 84880040113     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0106-6     Document Type: Article

References (39)

1. Barch, D.M. 2004. Pharmacological manipulation of human working memory. Psychopharmacology (Berl) 174: 126-135.
2. Braff, D.L., M.A. Geyer, and N.R. Swerdlow. 2001. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258.
3. 1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. International Journal of Neuropsychopharmacology 12: 873-883.
4. Calabrese, E.J., and L.A. Baldwin. 2001. U-shaped dose-responses in biology, toxicology, and public health. Annual Review of Public Health 22: 15-33.
5. Chen, X.W., Y.Q. Feng, C.J. Hao, X.L. Guo, X. He, Z.Y. Zhou, N. Guo, H.P. Huang, W. Xiong, H. Zheng, P.L. Zuo, C.X. Zhang, W. Li, and Z. Zhou. 2008. DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. Journal of Cell Biology 181: 791-801.
6. 2 dopamine receptor blockers in the rat. Psychopharmacology (Berl) 110: 165-168.
7. Ennaceur, A. 2010. One-trial object recognition in rats and mice: Methodological and theoretical issues. Behavioural Brain Research 215: 244-254.
8. Eyjolfsson, E.M., E. Brenner, D. Kondziella, and U. Sonnewald. 2006. Repeated injection of MK801: An animal model of schizophrenia? Neurochemistry International 48: 541-546.
9. Fiszdon, J.M., and L.F. Reddy. 2012. Review of social cognitive treatments for psychosis. Clinical Psychology Review 32: 724-740.
10. Geyer, M.A., K. Krebs-Thomson, D.L. Braff, and N.R. Swerdlow. 2001. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117-154.
11. Geyer, M.A., B. Olivier, M. Joels, and R.S. Kahn. 2012. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends in Pharmacological Sciences 33: 515-521.
12. Goff, D.C., and J.T. Coyle. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158: 1367-1377.
13. Huen, M.S., J.W. Leung, W. Ng, W.S. Lui, M.N. Chan, J.T. Wong, and H. Xue. 2003. 5,7-Dihydroxy-6-methoxyflavone, a benzodiazepine site ligand isolated from Scutellaria baicalensis Georgi, with selective antagonistic properties. Biochemical Pharmacology 66: 125-132.
14. Jentsch, T.J., V. Stein, F. Weinreich, and A.A. Zdebik. 2002. Molecular structure and physiological function of chloride channels. Physiological Reviews 82: 503-568.
15. Joy, C.B., Adams, C.E., and Lawrie, S.M. 2006. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, CD003082.
16. Kim, D.H., S.J. Jeon, K.H. Son, J.W. Jung, S. Lee, B.H. Yoon, J.W. Choi, J.H. Cheong, K.H. Ko, and J.H. Ryu. 2006. Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacology, Biochemistry and Behavior 85: 658-668.
17. Kim, D.H., S.J. Jeon, K.H. Son, J.W. Jung, S. Lee, B.H. Yoon, J.J. Lee, Y.W. Cho, J.H. Cheong, K.H. Ko, and J.H. Ryu. 2007a. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiology of Learning and Memory 87: 536-546.
18. 25-35-induced memory impairment in mice. Neuropharmacology 55: 639-647.
19. Kim, D.H., B.H. Yoon, Y.W. Kim, S. Lee, B.Y. Shin, J.W. Jung, H.J. Kim, Y.S. Lee, J.S. Choi, S.Y. Kim, K.T. Lee, and J.H. Ryu. 2007b. The seed extract of Cassia obtusifolia ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice. Journal of Pharmacological Science 105: 82-93.
20. Konradi, C., and S. Heckers. 2003. Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment. Pharmacology & Therapeutics 97: 153-179.
21. Krystal, J.H., D.C. D'souza, D. Mathalon, E. Perry, A. Belger, and R. Hoffman. 2003. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 169: 215-233.
22. Ma, J., and L.S. Leung. 2007. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology (Berl) 191: 961-974.
23. Miyamoto, S., G.E. Duncan, C.E. Marx, and J.A. Lieberman. 2005. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10: 79-104.
24. Nakazawa, K., V. Zsiros, Z. Jiang, K. Nakao, S. Kolata, S. Zhang, and J.E. Belforte. 2012. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62: 1574-1583.
25. Powell, C.M., and T. Miyakawa. 2006. Schizophrenia-relevant behavioral testing in rodent models: A uniquely human disorder? Biological Psychiatry 59: 1198-1207.
26. Rubio, M.D., J.B. Drummond, and J.H. Meador-Woodruff. 2012. Glutamate receptor abnormalities in Schizophrenia: Implications for innovative treatments. Biomolecules & Therapeutics 20: 1-18.
27. -3 secretion in CF. American Journal of Physiology 276: C16-C25.
28. Tuominen, H.J., J. Tiihonen, and K. Wahlbeck. 2005. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 72: 225-234.
29. Van Os, J., and S. Kapur. 2009. Schizophrenia. Lancet 374: 635-645.
30. Verkman, A.S., M.C. Sellers, A.C. Chao, T. Leung, and R. Ketcham. 1989. Synthesis and characterization of improved chloride-sensitive fluorescent indicators for biological applications. Analytical Biochemistry 178: 355-361.
31. Wallace, T.L., P.M. Callahan, A. Tehim, D. Bertrand, G. Tombaugh, S. Wang, W. Xie, W.B. Rowe, V. Ong, E. Graham, A.V. Terry Jr, J.S. Rodefer, B. Herbert, M. Murray, R. Porter, L. Santarelli, and D.A. Lowe. 2011. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. Journal of Pharmacology and Experimental Therapeutics 336: 242-253.
32. Weber, M., and N.R. Swerdlow. 2008. Rat strain differences in startle gating-disruptive effects of apomorphine occur with both acoustic and visual prepulses. Pharmacology, Biochemistry and Behavior 88: 306-311.
33. West, M.R., and C.R. Molloy. 1996. A microplate assay measuring chloride ion channel activity. Analytical Biochemistry 241: 51-58.
34. Wong, A.H., and H.H. Van Tol. 2003. Schizophrenia: from phenomenology to neurobiology. Neuroscience and Biobehavioral Reviews 27: 269-306.
35. 6 receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. British Journal of Pharmacology 167: 436-449.
36. Wykes, T., C. Reeder, S. Landau, B. Everitt, M. Knapp, A. Patel, and R. Romeo. 2007. Cognitive remediation therapy in schizophrenia: Randomised controlled trial. British Journal of Psychiatry 190: 421-427.
37. Yoon, S.Y., I.C. Dela Pena, C.Y. Shin, K.H. Son, Y.S. Lee, J.H. Ryu, J.H. Cheong, and K.H. Ko. 2011. Convulsion-related activities of Scutellaria flavones are related to the 5,7-dihydroxyl structures. European Journal of Pharmacology 659: 155-660.
38. Young, J.W., S.B. Powell, and M.A. Geyer. 2012. Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology 62: 1381-1390.
39. Zarrindast, M.R., T. Shamsi, P. Azarmina, P. Rostami, and B. Shafaghi. 2004. GABAergic system and imipramine-induced impairment of memory retention in rats. European Neuropsychopharmacology 14: 59-64.